The reiteration of an Overweight rating by Goldman Sachs analyst Rajan Sharma indicates a positive outlook for Immunocore Holdings. The maintained $79 price target suggests that the stock is expected to perform well in the short term. This news is highly relevant and important for investors in IMCR, as it comes from a reputable financial institution and analyst.